Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients

Abstract Aims Hyperkalaemia is observed frequently in heart failure (HF) patients and is associated with an impaired prognosis and underuse of mineralocorticoid receptor antagonists (MRAs). However, the effects of serum potassium on prescription of the full guideline recommended daily dose of 50 mg...

Full description

Bibliographic Details
Main Authors: Pascal R. D. Clephas, Sumant P. Radhoe, Gerard C. M. Linssen, Jorina Langerveld, Jacobus Plomp, Jeroen P. P. Smits, Michiel J. Nagelsmit, Hans‐Peter Brunner‐La Rocca, Jasper J. Brugts
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:ESC Heart Failure
Subjects:
Heart failure
Heart failure with reduced ejection fraction
Hyperkalaemia
Mineralocorticoid receptor antagonists
Renin‐angiotensin‐aldosterone system inhibitors
Guidelines
Online Access:https://doi.org/10.1002/ehf2.14285

Internet

https://doi.org/10.1002/ehf2.14285

Similar Items